ReviewFrontiers in pharmacology2018
A Review on the Synthesis and Bioactivity Aspects of Beauvericin, a
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 100 citations in OpenAlex.
- Occurrence and Co-Occurrence of Regulated and Emerging Mycotoxins in Foods Marketed to U.S. Toddlers.International journal of environmental research and public health · 2026Article
- Potentiating Effect of Beauvericin on Colistin, a Last Resort Antibiotic in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Anti-mycobacterial, cytotoxic effects of Penicillium mallochii ethanol extract, and quantitative detection of its extrolites by lc-q-tof-ms/ms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Histidinol-Phosphate Phosphatase FoHis2 Is Essential for Growth, Stress Responses, and Full Virulence inJournal of fungi (Basel, Switzerland) · 2026Article
- Integrated polyphasic characterization and mycotoxin production of fungal isolates in sugarcane (Frontiers in nutrition · 2026Article
- Fungal diversity and mycotoxins in retail polished and unpolished rice in Thailand.Frontiers in nutrition · 2026Article
- Biosynthesis Regulation of Secondary Metabolite Production inJournal of fungi (Basel, Switzerland) · 2025Review
- Compact Conformation of BaThe journal of physical chemistry letters · 2025Article
- The mycotoxin Beauvericin is an uncompetitive inhibitor of Cathepsin B.Protein science : a publication of the Protein Society · 2025Article
- Article
- In vitro assessment of emerging mycotoxins co-occurring in cheese: a potential health hazard.Archives of toxicology · 2024Article
- Anti-tumor activity of beauvericin: focus on intracellular signaling pathways.Mycotoxin research · 2024Review
- What are the 100 most cited fungal genera?Studies in mycology · 2024Article
- Toxicological evaluation of microbial secondary metabolites in the context of European active substance approval for plant protection products.Environmental health : a global access science source · 2024Review
- Review
- Non-ribosomal peptide synthetase (NRPS)-encoding products and their biosynthetic logics in Fusarium.Microbial cell factories · 2024Review
- First Total Syntheses of Beauvericin A andACS omega · 2024Article
- Endophytic fungi as a potential source of anti-cancer drug.Archives of microbiology · 2024Review
- Next generation sequencing-aided screening, isolation, molecular identification, and antimicrobial potential for bacterial endophytes from the medicinal plant,Frontiers in microbiology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beauvericin (BEA) is an emerging
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.